Novo Nordisk's Oral Cardiovascular Drug Trial Achieves Primary Objective
Novo Nordisk Announced SOUL Cardiovascular Outcomes Trial Achieved Its Primary Objective By Demonstrating A Statistically Significant And Superior Reduction In MACE Of 14% For People Treated With Oral Semaglutide Vs Placebo
'FDA Won't Take Action Against GLP-1 Compounders As It Rethinks Tirzepatide Shortage' - Endpoints News
European Equities Close Mostly Higher in Friday Trading; Novo Nordisk's Catalent Acquisition Faces Roadblock
Viking Stock Rises 29% in Three Months: Time to Buy, Hold or Sell?
Weight loss drug expansion plan faces obstacles! Consumer groups in the USA demand the FTC to block the shareholders of novo-nordisk a/s from acquiring catalent.
On Thursday, consumer groups and two large unions in the usa urged the Federal Trade Commission (FTC) to block the acquisition contract of drug manufacturer catalent by novo-nordisk a/s shareholder Novo Holdings.